肿瘤免疫之王要变了?康方生物依沃西在OS数据上战胜PD-1单抗

第一财经
Jun 01

康方生物(09926.HK)的PD-1/VEGF双抗依沃西,在药物临床价值评估“金标准”OS(总生存期)上的数据如何,牵动业界以及资本市场的神经。  6月1日,在2026年美国临床肿瘤学会(ASCO)年会上,康方生物公布了依沃西联合化疗对比替雷利珠单抗联合化疗,一线治疗晚期鳞状非小细胞肺癌(sq-NSCLC)III期HARMONi-6/AK112-306研究的OS显著阳性结果。  研究结果显示,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10